ClinicalTrials.gg
CompletedNCT01236391PCYC-1104-CAUpdated Aug 28, 2015Results posted

Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

A Phase 2 interventional study of PCI-32765 in Mantle Cell Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 18 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-28.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
115
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 45 studies testing ibrutinib in Lymphoma, Mantle-Cell — 2 open to participants now, 16 under way, 2 of them phase 3. ibrutinib · Lymphoma, Mantle-Cell.

Enrollment
9th of 45
115 · median 39
Started
2011
the only one that year
Phase 2
21 of 45
none open now
Registered
3rd of 45
by date
Lead sponsor
3 of 45
Pharmacyclics LLC.

Among the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, this one is the 9th largest by enrollment, is the only one that started in 2011, is one of 21 in phase 2, and was the 3rd registered.

Lymphoma, Mantle-Cell

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

2 of the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

The primary objective of this study was to evaluate the efficacy of ibrutinib in participants with relapsed or refractory MCL.

The secondary objective was to evaluate the safety of a fixed daily dosing regimen (560 mg daily) of PCI-32765 in this population.

Read the detailed description

This is a Phase 2, open-label, nonrandomized, multicenter, monotherapy study in subjects with histologically documented MCL who have relapsed after ≥ 1 (but not > 5) prior treatment regimens. All subjects meeting eligibility criteria will receive PCI-32765 capsules at a dosage of 560 mg/day once daily for a 28-day cycle until disease progression, unacceptable toxicity, or enrollment in a long-term extension study, whichever occurs earlier.

03

Conditions studied

  • Mantle Cell Lymphoma

Keywords

  • Pharmacyclics
  • Mantle
  • Mantle Cell
  • Lymphoma
  • Non-Hodgkins
  • Bortezomib
  • Velcade
  • Naive
  • PCYC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Men and women ≥ 18 years of age
  • performance status of ≤ 2
  • confirmed MCL, with documentation of either overexpression of cyclin D1 or t(11;14), and on cross sectional imaging that is ≥ 2 cm in the longest diameter and measurable in 2 perpendicular dimensions
  • Documented failure to achieve at least partial response (PR) with, or documented disease progression disease after, the most recent treatment regimen
  • At least 1, but no more than 5, prior treatment regimens for MCL (Note: Subjects having received ≥2 cycles of prior treatment with bortezomib, either as a single agent or as part of a combination therapy regimen, will be considered to be bortezomib-exposed.)
  • Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty
  • Ability to understand the purpose and risks of the study and provide signed and dated and authorization to use protected health information (in accordance with national and local subject privacy regulations)

Major exclusion criteria:

  • Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy within 3 weeks, or major surgery within 2 weeks of first dose of study drug
  • Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of PCI-32765 capsules, or put the study outcomes at undue risk
  • cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the Functional Classification
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
  • Any of the following laboratory abnormalities:

    1. (ANC) \< 750 cells/mm3 (0.75 x 109/L) unless there is documented bone marrow involvement
    2. count \< 50,000 cells/mm3 (50 x 109/L) independent of transfusion support unless there is documented bone marrow involvement
    3. Serum (AST/SGOT) or alanine transaminase (ALT/SGPT) ≥ 3.0 x (ULN)
    4. Creatinine > 2.0 x ULN
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    Participants received PCI-32765 560 mg daily

    Participants were enrolled and received 560 mg/day dose, stratified into 2 groups based on prior bortezomib exposure.

    Drug: PCI-32765

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Response

    The primary endpoint of the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR), according to the revised International Working Group Criteria for non-Hodgkin's lymphoma (Cheson et al, 2007), as assessed by the investigator. CR is a complete disappearance of all disease, no new lesions, lymph nodes must have regressed and be PET negative, spleen and liver should not be palpable and without nodules, and bone marrow must be negative. PR is a \>/= 50% decrease in the sum of the product of diameters of the target lesions, and \>/= 50% decrease of splenic and hepatic nodules from baseline, no new lesions and no increase in the size of liver, spleen or non-target lesions.

    Time frame: The median follow-up time on study for all treated participants is 15.3 (range 1.9 - 22.3) months

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AEs)

    Number of participants who had experienced at least one treatment emergent AE

    Time frame: From first dose of PCI-32765 to within 30 days of last dose for each participant or until study closure

  2. PCI-32765 and Its Metabolite (PCI-45227) AUC0-24h After Repeat Dosing of PCI-32765

    Area under the plasma concentration-time curve using data collected at 0, 1, 2, 4, 6-8, and 24 hours post dose (AUC0-24h)

    Time frame: Performed During the First Month of Receiving PCI-32765

  3. Mean Change From Baseline to Cycle 5 in EORTC QLQ-C30 Global Health Status Score

    Mean change from baseline to Cycle 5 in the European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) Global Health Status Score according to EORTC QLQ-C30 Scoring Manual (3rd Edition, 2001). For global health status, positive changes indicated better health status or functioning, and negative changes indicated worsening of health status or functioning. Scale scores range from 0 to 100. A change in 5 to 10 points in either direction represents a small change; 10 to 20 points represents a moderate change and greater than 20 points represents a large change.

    Time frame: From Baseline to Cycle 5 (Week 20)

07

Results

Posted Mar 13, 2015

Participant flow

Participant flow — Overall Study
MilestonePCI-32765
Started111
Completed95
Not completed16

Outcome measures

PrimaryPercentage of Participants Achieving Response

The primary endpoint of the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR), according to the revised International Working Group Criteria for non-Hodgkin's lymphoma (Cheson et al, 2007), as assessed by the investigator. CR is a complete disappearance of all disease, no new lesions, lymph nodes must have regressed and be PET negative, spleen and liver should not be palpable and without nodules, and bone marrow must be negative. PR is a \>/= 50% decrease in the sum of the product of diameters of the target lesions, and \>/= 50% decrease of splenic and hepatic nodules from baseline, no new lesions and no increase in the size of liver, spleen or non-target lesions.

Time frame:
The median follow-up time on study for all treated participants is 15.3 (range 1.9 - 22.3) months
Reported as:
Number · percentage of participants with response
Percentage of Participants Achieving Response
percentage of participants with responsePCI-32765
Percentage of Participants Achieving Response67.6 (58.9 to 76.3)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs)

Number of participants who had experienced at least one treatment emergent AE

Time frame:
From first dose of PCI-32765 to within 30 days of last dose for each participant or until study closure
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (AEs)
participantsPCI-32765
Number of Participants With Treatment Emergent Adverse Events (AEs)111
SecondaryPCI-32765 and Its Metabolite (PCI-45227) AUC0-24h After Repeat Dosing of PCI-32765

Area under the plasma concentration-time curve using data collected at 0, 1, 2, 4, 6-8, and 24 hours post dose (AUC0-24h)

Time frame:
Performed During the First Month of Receiving PCI-32765
Reported as:
Mean · AUC0-24h (ng*h/mL)
PCI-32765 and Its Metabolite (PCI-45227) AUC0-24h After Repeat Dosing of PCI-32765
AUC0-24h (ng*h/mL)PCI-32765 - Day 8PCI-45227 (Metabolite)- Day 8
PCI-32765 and Its Metabolite (PCI-45227) AUC0-24h After Repeat Dosing of PCI-32765953 ± 7051263 ± 707
SecondaryMean Change From Baseline to Cycle 5 in EORTC QLQ-C30 Global Health Status Score

Mean change from baseline to Cycle 5 in the European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) Global Health Status Score according to EORTC QLQ-C30 Scoring Manual (3rd Edition, 2001). For global health status, positive changes indicated better health status or functioning, and negative changes indicated worsening of health status or functioning. Scale scores range from 0 to 100. A change in 5 to 10 points in either direction represents a small change; 10 to 20 points represents a moderate change and greater than 20 points represents a large change.

Time frame:
From Baseline to Cycle 5 (Week 20)
Reported as:
Mean · scores on a scale
Mean Change From Baseline to Cycle 5 in EORTC QLQ-C30 Global Health Status Score
scores on a scaleEORTC QLQ-C30
Mean Change From Baseline to Cycle 5 in EORTC QLQ-C30 Global Health Status Score0.6 ± 22.4

Adverse events

Collected over From first dose of PCI-32765 to within 30 days of last dose. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PCI-32765—62/111 (55.9%)111/111 (100%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventPCI-32765
Mantle cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)8/111
PneumoniaInfections and infestations6/111
Atrial fibrillationCardiac disorders5/111
Urinary tract infectionInfections and infestations4/111
Febrile neutropeniaBlood and lymphatic system disorders3/111
Abdominal painGastrointestinal disorders3/111
Oedema peripheralGeneral disorders3/111
PyrexiaGeneral disorders3/111
Subdural haematomaInjury, poisoning and procedural complications3/111
Renal failure acuteRenal and urinary disorders3/111
Most frequent other events
Showing 10 of 388
Most frequent other events
EventPCI-32765
DiarrhoeaGastrointestinal disorders55/111
FatigueGeneral disorders46/111
NauseaGastrointestinal disorders34/111
Oedema peripheralGeneral disorders30/111
DyspnoeaRespiratory, thoracic and mediastinal disorders29/111
ConstipationGastrointestinal disorders28/111
Upper respiratory tract infectionInfections and infestations26/111
VomitingGastrointestinal disorders25/111
Decreased appetiteMetabolism and nutrition disorders24/111
NeutropeniaBlood and lymphatic system disorders20/111

Baseline characteristics

One hundred fifteen subjects were enrolled and 111 subjects received at least 1 dose of ibrutinib and constitute the all treated population and the safety analysis set.

Age, Categorical
Age, Categorical(Participants)PCI-32765
<=18 years0
Between 18 and 65 years41
>=65 years70
Age, Continuous
Age, Continuous(years)PCI-32765
Mean67.1 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)PCI-32765
Female26
Male85
Region of Enrollment
Region of Enrollment(participants)PCI-32765
United States78
Poland10
Germany3
United Kingdom20
08

Study locations

18 sites
  • Stanford University School of Medicine
    Stanford, California 94305, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Cll Research and Treatment Program
    New Hyde Park, New York 11042, United States
  • New York Presbyterian Hospital/Cornell Medical Center
    New York, New York 94305, United States
  • The Ohio Sate university
    Columbus, Ohio 43210, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Virginia School of Medicine Hospital
    Charlottesville, Virginia 22908, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Klinikum der Universitat Munchen - Campus Grosshadern
    Munchen, D - 81377, Germany
  • Universitatsklinikum Ulm, Klinik fur Innere Medizin II
    ULM, 89081, Germany
  • Oddzail Kliniczny Onkologil
    Bydgoszcz, 85-796, Poland
  • Malopolskie Centrum Medyczne
    Krakow, 30-510, Poland
  • MTZ Clinical Research Sp. z o.o.
    Warsaw, 02-106, Poland
  • Centre for Experimental Cancer Medicine
    London, EC1M6BQ, United Kingdom
  • Christie Hospital
    Manchester, M20 4BX, United Kingdom
  • Derriford Hospital
    Plymouth, PL6 8DH, United Kingdom
  • Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015 Aug 6;126(6):739-45. doi: 10.1182/blood-2015-03-635326. Epub 2015 Jun 9. PubMed 26059948 ↗
  • Marostica E, Sukbuntherng J, Loury D, de Jong J, de Trixhe XW, Vermeulen A, De Nicolao G, O'Brien S, Byrd JC, Advani R, McGreivy J, Poggesi I. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemother Pharmacol. 2015 Jan;75(1):111-21. doi: 10.1007/s00280-014-2617-3. Epub 2014 Nov 8. PubMed 25381051 ↗
  • Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19. PubMed 23782157 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2010
First posted
Nov 8, 2010
Start
Feb 2011
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Mar 13, 2015
Last update
Aug 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01236391
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Nov 8, 2010
Start date
Feb 2011
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Mar 13, 2015
Last update
Aug 28, 2015

Study contacts

Darrin Beaupre, MD, PhD
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion